Advocacy intelligence hub — real-time data for patient organizations
Natalie Callander — PHASE1, PHASE2
Washington University School of Medicine — PHASE1
Eden Biltibo — PHASE2
National Cancer Institute (NCI) — PHASE2
Massachusetts General Hospital — PHASE2
Shanghai Hengrui Pharmaceutical Co., Ltd. — PHASE1
Regeneron Pharmaceuticals — PHASE3
Regeneron Pharmaceuticals — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance23
Abecma
Celgene Corporation, a Bristol-Myers Squibb Company
Melphalan
Sagent
Thalomid
Celgene
Darzalex Faspro
Janssen
Sarclisa
Sanofi
Carvykti
Janssen Research & Development, LLC
Blenrep
GlaxoSmithKline
TALVEY
Janssen
EMPLICITI
Bristol Myers Squibb
Bortezomib
Takeda
Farydak
zr pharma& GmbH
TECVAYLI
Janssen
KYPROLIS
Amgen
Pomalidomide
Bristol Myers Squibb
Lenalidomide
Bristol Myers Squibb
Mozobil
Sanofi
LYNOZYFIC
Unknown
XPOVIO
Karyopharm
PLERIXAFOR
Sanofi
APHEXDA
BioLineRx
Elrexfio
Pfizer
VELCADE
Takeda
NINLARO
Takeda
Lynozyfic
(linvoseltamab-gcpt)Orphan drugRegeneron Pharmaceuticals, Inc.
12.1 Mechanism of Action Linvoseltamab-gcpt is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cell...
Abecma
(idecabtagene vicleucel)Orphan drugCelgene Corporation, a Bristol-Myers Squibb Company
12.1 Mechanism of Action ABECMA is a chimeric antigen receptor (CAR)-positive T cell therapy targeting B-cell maturation antigen (BCMA), which is expr...
Talvey
(talquetamab-tgvs)Orphan drugJanssen Biotech, inc.
12.1 Mechanism of Action Talquetamab-tgvs is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells ...
Tecvayli
(teclistamab-cqyv)Orphan drugJanssen Biotech, Inc.
12.1 Mechanism of Action Teclistamab-cqyv is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells ...
Carvykti
(ciltacabtagene autoleucel)Orphan drugJanssen Research & Development, LLC
12.1 Mechanism of Action CARVYKTI is a BCMA-directed, genetically modified autologous T cell immunotherapy, which involves reprogramming a patient's o...
Kyprolis
(carfilzomib)Orphan drugOnyx Therapeutics, Inc.
Proteasome Inhibitor [EPC]
12.1 Mechanism of Action Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing...
BLENREP
(belantamab mafodotin-blmf)Orphan drugGlaxoSmithKline Intellectual Property Development Ltd.
12.1 Mechanism of Action Belantamab mafodotin‑blmf is an antibody‑drug conjugate (ADC). The antibody component is an afucosylated IgG1 directed agains...
Sarclisa
(isatuximab-irfc)Orphan drugSanofi-Aventis U.S. LLC
CD38-directed Cytolytic Antibody [EPC]
12.1 Mechanism of Action Isatuximab-irfc is an IgG1-derived monoclonal antibody that binds to CD38 expressed on the surface of hematopoietic and tumor...
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).
Monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) are among the backbones of treatment for relapsed/refractory multiple myeloma (RRMM). Beyond current standard-of-care regimens, the rol...
Targeting the FOXM1/BUB1B signaling network in multiple myeloma: mechanistic insights and therapeutic potential.
Multiple myeloma (MM) is a plasma cell cancer characterized by genomic instability and drug resistance. The FOXM1 transcription factor and the BUB1B kinase are pivotal drivers of this malignancy. FOXM...
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.
The rapid expansion of therapeutic options for multiple myeloma (MM) has created uncertainty regarding optimal sequencing and clinical application. To address gaps in evidence, the 2025 Bridging the G...
Targeted immunoPET imaging of multiple myeloma.
Current standard of care methods of imaging multiple myeloma disease burden are suboptimal. For example, fluorodeoxyglucose-(FDG)-PET/CT may fail to detect up to 50% of myeloma lesions. Immunologicall...
Talquetamab in Japanese patients with relapsed/refractory multiple myeloma in the MonumenTAL-1 study.
Talquetamab is the first G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). We report ...
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).
Multiple myeloma (MM) with t(11;14)(CCND1;IGH) remains the only subset sensitive to the BCL2 inhibitor venetoclax. However, not all patients with t(11;14)(CCND1;IGH) respond to treatment, and some pro...
Cyrille TOUZEAU, Prof
CHU Nantes France
Aurore PERROT, Prof
IUCT Toulouse France
He Huang, MD
Zhejiang University
📍 Hanzhou, Zhejiang
Heather Landau, MD, M.D
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY
Thomas Martin, MD
University of California, San Francisco
Ying Lu
The Affiliated People's Hospital of Ningbo University